Four China COVID-19 Vaccines Safe in 60,000 Phase III Subjects

Four China biopharmas have dosed a total of 60,000 people in Phase III trials of their respective COVID-19 vaccines without causing any serious adverse reactions. The news did not include any reports on the vaccines' efficacy, which must wait for more data. At a news conference, Zheng Zhongwei, head of China ’s COVID-19 vaccine development task force, said China is expected to produce as many as 610 million vaccine doses by the end of this year. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.